OXFORD BIOMEDICA ORD 50P news, videos and press releases - Page 2
For more news please use our advanced search feature.
OXFORD BIOMEDICA ORD 50P - More news...
OXFORD BIOMEDICA ORD 50P - More news...
- Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis
- Oxford Biomedica announces strategic investment by Serum Life Sciences Ltd
- Oxford Biomedica Plc INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021
- Oxford Biomedica (OXB): Driving innovation in a thriving CGT industry
- Edison Investment Research Limited: Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution
- Oxford Biomedica (OXB): Vector Innovation Key to Cell and Gene Evolution
- Oxford Biomedica Interim Results
- Edison Issues Outlook on Oxford Biomedica (OXB)
- Oxford Biomedica notes the Japanese approval of Kymriah® (tisagenlecleucel), the first CAR-T cell therapy authorised in Asia
- Oxford Biomedica plc: Preliminary results for the year ended 31 December 2018
- Oxford BioMedica notes that Axovant doses first patient in clinical study of AXO-Lenti-PD, a novel gene therapy for patients with Parkinson’s disease
- OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2018
- Oxford BioMedica announces further capacity expansion with new facility
- Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval
- Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim and Imperial Innovations Form Partnership to Develop a Novel Gene Therapy Treatment for Cystic Fibrosis
- Oxford BioMedica Announces Collaboration and Licence Agreement with Bioverativ in the Field of Haemophilia Gene Therapy
- Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCL
- Oxford BioMedica plc: Oxford BioMedica notes FDA Advisory Committee to review CTL019
-
Oxford Biomedica plans biological and economic balance
-
Oxford BioMedica
-
Oxford BioMedica
